Home > Result Summaries: Compounds > ropinirole > Result Summary for 101468/206

Result Summary for 101468/206

Result Summary

Protocol ID:	101468/206
Clinical Study ID:	101468/206
Official Title:	A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS)
Phase:	phase 3
Study Indications or Diseases:	Restless Legs Syndrome
Generic Name:	ropinirole
Trade/Product Name:	Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	C Hill-Zabala, R Bogan, D Lee, M Lomax. A 52-week open-label study to assess the long-term tolerability of Ropinirole CR Extended Release Tablets in subjects with Restless Legs Syndrome (RLS). 12th International Congress of Parkinson’s Disease and Movement Disorders, Chicago, IL, June 22-26, 2008 (abstract 1112).